National Policy Resources—Local Advocacy Results

As cancer care professionals who experience the challenges of providing quality cancer care first-hand, MSCO members are well positioned to educate decision-makers on how coverage and reimbursement issues affect community oncology. State and federal legislation can have a significant impact on the financial viability of local cancer programs, which is why it's so important that our members make their voices heard.

In an effort to provide resources needed to effectively advocate on the issues that are important to them, our redesigned advocacy webpage features activity from the Centers for Medicare & Medicaid Services (CMS), national healthcare coverage through the Association of Community Cancer Centers (ACCC), local news articles and webinars, and more.

We want to hear from you! If there is a specific piece of legislation you want to know more about, an important resource we're missing, or if you want to get more involved, please contact us!


State Advocacy

MSCO Joins in Support Letter for HF 3717 and Its Provisions to Address Out-of-Pocket Costs for Patients

The Minnesota Society of Clinical Oncology (MSCO) joined national organizations in a support letter for copy-only bill language in HF 3717 inspired by HF 633 (Bierman) and SF 365 (Nelson). This language would give consumers who purchase coverage on the individual and small-group markets the option of buying a plan that restructures the out-of-pocket costs for prescription drugs.

Read Letter

Federal Advocacy

MSCO Joins Coalition Letter Urging Addition of the Cures 2.0 Concept Paper Title IV Provisions in the Next COVID-19 Relief Package

The Minnesota Society of Clinical Oncology (MSCO) joined in a coalition letter to congressional leadership urging that Congress include the 21st Century Cures 2.0 concept paper, recently released by Representatives Diana DeGette and Fred Upton in upcoming legislation to further address the COVID-19 public health crisis. Specifically the letter urges leadership to include policy to provide Medicaid coverage of the routine care costs of clinical trials participation for patients with life-threatening conditions in every state. This critical protection is championed by Representatives Ben Ray Luján and Gus Bilirakis in the Clinical Treatment Act (H.R. 913).

 

FROM THE ACCCBUZZ BLOG

Advocacy In the News

CMS Announces CY 2023 PFS Proposed Rule

On July 7, the Centers for Medicare & Medicaid Services (CMS) released the Calendar Year (CY) 2023 Physician Fee Schedule (PFS) proposed rule, which would significantly expand access to behavioral health services, Accountable Care Organizations (ACOs), cancer screening, and dental care—particularly in rural and underserved areas.

“Integrated coordinated, whole-person care—which addresses physical health, behavioral health, and social determinants of health—is crucial for people with Medicare, especially those with complex needs,” said Dr. Meena Seshamani, deputy administrator at CMS and director of the Center for Medicare. “If finalized, the proposals in this rule will advance equity, lead to better care, support healthier populations, and drive smarter spending of the Medicare dollar.

For more information, read the proposed rule as well as the CMS press release and fact sheet.

Posted 7/8/2022

Oncology State Societies at ACCC: Snapshot from the 2022 ASCO Annual Meeting

In this clip, Stephanie Van Winkle, Executive Director of the Oncology State Societies at ACCC, gives an overview of the important work the Oncology State Societies does to empower its members around state and federal advocacy issues, and help them support cancer care delivery in their state. Join today


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
msco-minnesota.com
Email Us